This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Valcuria Ab. Active years: 2018.
Company Filing History:
Years Active: 2018
Title: Thomas Relander: Innovator in Pharmaceutical Composition
Introduction
Thomas Relander is a notable inventor based in Lund, Sweden. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compositions that aid in cancer treatment. His innovative approach combines various compounds to enhance therapeutic efficacy.
Latest Patents
Relander holds a patent for a pharmaceutical composition comprising an HDAC inhibitor and a steroid. This composition is designed for use in cancer treatment, serving as a pretreatment prior to other therapies. The patent outlines the potential for the HDAC inhibitor or steroid to be administered separately, providing flexibility in treatment protocols.
Career Highlights
Throughout his career, Thomas Relander has focused on advancing medical treatments through innovative pharmaceutical solutions. His work has garnered attention for its potential impact on cancer therapy, showcasing his commitment to improving patient outcomes.
Collaborations
Relander collaborates with Kristina Drott, contributing to the development of new pharmaceutical strategies. Their partnership exemplifies the collaborative spirit in the research community, aimed at tackling complex medical challenges.
Conclusion
Thomas Relander's contributions to pharmaceutical innovation highlight the importance of research in developing effective cancer treatments. His work continues to inspire advancements in the medical field.